Tissue-specific regulation of genes by estrogen receptors

Seminars in Reproductive Medicine

Volumn 30, Issue 1, 2012, Pages 14-22

  Leitman, Dale C ^a   Paruthiyil, Sreenivasan ^b   Yuan, Chaoshen ^a   Herber, Candice B ^a   Olshansky, Moshe ^c   Tagliaferri, Mary ^b   Cohen, Isaac ^b   Speed, Terence P ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Bionovo Inc   (United States)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

estradiol; estrogen; estrogen receptor; gene regulation; transcription

Indexed keywords

4,4',4''(4 PROPYL [1H] PYRAZOLE 1,3,5 TRIYL)TRISPHENOL; DIARYLPROPIONITRILE; ESTRADIOL; ESTROGEN; ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; LIQUIRITIGENIN; MF 101; PHENOL DERIVATIVE; PRINABEREL; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ARTICLE; BONE; BRAIN; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RISK; DIABETES MELLITUS; ENDOMETRIUM CANCER; EPIGENETICS; ESTROGEN THERAPY; GENE CONTROL; GENETIC TRANSCRIPTION; HUMAN; MENOPAUSAL SYNDROME; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PROTEIN BINDING; PROTEIN EXPRESSION; THROMBOEMBOLISM; TISSUE SPECIFICITY;

ANIMALS; ANTI-OBESITY AGENTS; ANTICARCINOGENIC AGENTS; DIABETES MELLITUS, TYPE 2; EPIGENESIS, GENETIC; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; METABOLIC SYNDROME X; MOLECULAR TARGETED THERAPY; NEOPLASMS; OBESITY; ORGAN SPECIFICITY; RESPONSE ELEMENTS;

EID: 84856305300     PISSN: 15268004     EISSN: 15264564     Source Type: Journal    
DOI: 10.1055/s-0031-1299593     Document Type: Article

References (85)

1. Rossouw JE, Anderson GL, Prentice RL., et al. Writing Group for the Womens Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Womens Health Initiative randomized controlled trial. JAMA: 2002; 288 3 321 333 (Pubitemid 34761611)
2. Santen RJ, Allred DC, Ardoin SP., et al. Endocrine Society. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab: 2010; 95 7, Suppl 1 s1 s66
3. Anderson GL, Limacher M, Assaf AR., et al. Womens Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Womens Health Initiative randomized controlled trial. JAMA: 2004; 291 14 1701 1712 (Pubitemid 38489892)
4. Ettinger B, Grady D, Tosteson AN, Pressman A, Macer JL. Effect of the Womens Health Initiative on womens decisions to discontinue postmenopausal hormone therapy. Obstet Gynecol: 2003; 102 6 1225 1232 (Pubitemid 37518400)
5. LaCroix AZ, Chlebowski RT, Manson JE., et al. WHI Investigators. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA: 2011; 305 13 1305 1314
6. Kuiper GG, Carlsson B, Grandien K., et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology: 1997; 138 3 863 870 (Pubitemid 27089735)
7. Zhu BT, Han GZ, Shim JY, Wen Y, Jiang XR. Quantitative structure-activity relationship of various endogenous estrogen metabolites for human estrogen receptor alpha and beta subtypes: insights into the structural determinants favoring a differential subtype binding. Endocrinology: 2006; 147 9 4132 4150 (Pubitemid 44274976)
8. Heldring N, Pike A, Andersson S., et al. Estrogen receptors: how do they signal and what are their targets. Physiol Rev: 2007; 87 3 905 931 (Pubitemid 47084672)
9. Brandenberger AW, Tee MK, Lee JY, Chao V, Jaffe RB. Tissue distribution of estrogen receptors alpha (ER-alpha) and beta (ER-beta) mRNA in the midgestational human fetus. J Clin Endocrinol Metab: 1997; 82 10 3509 3512 (Pubitemid 27419113)
10. Couse JF, Lindzey J, Grandien K, Gustafsson JA, Korach KS. Tissue distribution and quantitative analysis of estrogen receptor-alpha (ERalpha) and estrogen receptor-beta (ERbeta) messenger ribonucleic acid in the wild-type and ERalpha-knockout mouse. Endocrinology: 1997; 138 11 4613 4621 (Pubitemid 27460895)
11. Hewitt SC, Harrell JC, Korach KS. Lessons in estrogen biology from knockout and transgenic animals. Annu Rev Physiol: 2005; 67 285 308 (Pubitemid 40404493)
12. Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res: 2004; 64 1 423 428 (Pubitemid 38114127)
13. Strm A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson JA. Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci U S A: 2004; 101 6 1566 1571 (Pubitemid 38236167)
14. Hartman J, Edvardsson K, Lindberg K., et al. Tumor repressive functions of estrogen receptor beta in SW480 colon cancer cells. Cancer Res: 2009; 69 15 6100 6106
15. Paruthiyil S, Cvoro A, Tagliaferri M, Cohen I, Shtivelman E, Leitman DC. Estrogen receptor causes a G2 cell cycle arrest by inhibiting CDK1 activity through the regulation of cyclin B1, GADD45A, and BTG2. Breast Cancer Res Treat: 2011; 129 3 777 784
16. Minutolo F, Macchia M, Katzenellenbogen BS, Katzenellenbogen JA. Estrogen receptor ligands: recent advances and biomedical applications. Med Res Rev: 2011; 31 3 364 442
17. Meyers MJ, Sun J, Carlson KE, Marriner GA, Katzenellenbogen BS, Katzenellenbogen JA. Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J Med Chem: 2001; 44 24 4230 4251 (Pubitemid 33095330)
18. Harris HA, Albert LM, Leathurby Y., et al. Evaluation of an estrogen receptor-beta agonist in animal models of human disease. Endocrinology: 2003; 144 10 4241 4249 (Pubitemid 37204818)
19. Cvoro A, Paruthiyil S, Jones JO., et al. Selective activation of estrogen receptor-beta transcriptional pathways by an herbal extract. Endocrinology: 2007; 148 2 538 547 (Pubitemid 46150775)
20. Mersereau JE, Levy N, Staub RE., et al. Liquiritigenin is a plant-derived highly selective estrogen receptor beta agonist. Mol Cell Endocrinol: 2008; 283 1-2 49 57
21. Grady D, Sawaya GF, Johnson KC., et al. MF101, a selective estrogen receptor beta modulator for the treatment of menopausal hot flushes: a phase II clinical trial. Menopause: 2009; 16 3 458 465
22. Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science: 1990; 247 4940 322 324
23. Giroux V, Bernatchez G, Carrier JC. Chemopreventive effect of ER-selective agonist on intestinal tumorigenesis in Apc(Min/+) mice. Mol Carcinog: 2011; 50 5 359 369
24. Shaaban AM, ONeill PA, Davies MP., et al. Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia. Am J Surg Pathol: 2003; 27 12 1502 1512 (Pubitemid 37486611)
25. Mostafaie N, Kllay E, Sauerzapf E., et al. Correlated downregulation of estrogen receptor beta and the circadian clock gene Per1 in human colorectal cancer. Mol Carcinog: 2009; 48 7 642 647
26. Cvoro A, Yuan C, Paruthiyil S, Miller OH, Yamamoto KR, Leitman DC. Cross talk between glucocorticoid and estrogen receptors occurs at a subset of proinflammatory genes. J Immunol: 2011; 186 7 4354 4360
27. Cvoro A, Tatomer D, Tee MK, Zogovic T, Harris HA, Leitman DC. Selective estrogen receptor-beta agonists repress transcription of proinflammatory genes. J Immunol: 2008; 180 1 630 636
28. Shumaker SA, Legault C, Rapp SR., et al. WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Womens Health Initiative Memory Study: a randomized controlled trial. JAMA: 2003; 289 20 2651 2662 (Pubitemid 37430136)
29. Cauley JA, Robbins J, Chen Z., et al. Womens Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Womens Health Initiative randomized trial. JAMA: 2003; 290 13 1729 1738 (Pubitemid 37430623)
30. Jackson RD, Wactawski-Wende J, LaCroix AZ., et al. Womens Health Initiative Investigators. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the Womens Health Initiative randomized trial. J Bone Miner Res: 2006; 21 6 817 828 (Pubitemid 43787988)
31. Margolis KL, Bonds DE, Rodabough RJ., et al. Womens Health Initiative Investigators. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Womens Health Initiative Hormone Trial. Diabetologia: 2004; 47 7 1175 1187 (Pubitemid 39093314)
32. Bonds DE, Lasser N, Qi L., et al. The effect of conjugated equine oestrogen on diabetes incidence: the Womens Health Initiative randomised trial. Diabetologia: 2006; 49 3 459 468 (Pubitemid 43277868)
33. Kanaya AM, Herrington D, Vittinghoff E., et al. Heart and Estrogen/progestin Replacement Study. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med: 2003; 138 1 1 9 (Pubitemid 36232088)
34. Stampfer MJ, Colditz GA, Willett WC., et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses health study. N Engl J Med: 1991; 325 11 756 762
35. van Seumeren I. Weight gain and hormone replacement therapy: are womens fears justified? Maturitas: 2000; 34 Suppl 1 S3 S8 (Pubitemid 30099642)
36. Polotsky HN, Polotsky AJ. Metabolic implications of menopause. Semin Reprod Med: 2010; 28 5 426 434
37. Espeland MA, Stefanick ML, Kritz-Silverstein D., et al. Postmenopausal Estrogen-Progestin Interventions Study Investigators. Effect of postmenopausal hormone therapy on body weight and waist and hip girths. J Clin Endocrinol Metab: 1997; 82 5 1549 1556 (Pubitemid 27200433)
38. Jensen LB, Vestergaard P, Hermann AP., et al. Hormone replacement therapy dissociates fat mass and bone mass, and tends to reduce weight gain in early postmenopausal women: a randomized controlled 5-year clinical trial of the Danish Osteoporosis Prevention Study. J Bone Miner Res: 2003; 18 2 333 342 (Pubitemid 36125926)
39. Mattiasson I, Rendell M, Trnquist C, Jeppsson S, Hulthn UL. Effects of estrogen replacement therapy on abdominal fat compartments as related to glucose and lipid metabolism in early postmenopausal women. Horm Metab Res: 2002; 34 10 583 588 (Pubitemid 35385609)
40. Gower BA, Muoz J, Desmond R, Hilario-Hailey T, Jiao X. Changes in intra-abdominal fat in early postmenopausal women: effects of hormone use. Obesity (Silver Spring): 2006; 14 6 1046 1055 (Pubitemid 46219706)
41. Maury E, Brichard SM. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol: 2010; 314 1 1 16
42. Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am: 2004; 33 2 283 303 (Pubitemid 38680631)
43. Potenza MV, Mechanick JI. The metabolic syndrome: definition, global impact, and pathophysiology. Nutr Clin Pract: 2009; 24 5 560 577
44. Cho GJ, Lee JH, Park HT., et al. Postmenopausal status according to years since menopause as an independent risk factor for the metabolic syndrome. Menopause: 2008; 15 3 524 529
45. Smith EP, Boyd J, Frank GR., et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med: 1994; 331 16 1056 1061 (Pubitemid 24317698)
46. Couse JF, Korach KS. Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev: 1999; 20 3 358 417 (Pubitemid 30654784)
47. Windahl SH, Vidal O, Andersson G, Gustafsson JA, Ohlsson C. Increased cortical bone mineral content but unchanged trabecular bone mineral density in female ERbeta(-/-) mice. J Clin Invest: 1999; 104 7 895 901 (Pubitemid 29536339)
48. Heine PA, Taylor JA, Iwamoto GA, Lubahn DB, Cooke PS. Increased adipose tissue in male and female estrogen receptor-alpha knockout mice. Proc Natl Acad Sci U S A: 2000; 97 23 12729 12734
49. Lindberg MK, Alatalo SL, Halleen JM, Mohan S, Gustafsson JA, Ohlsson C. Estrogen receptor specificity in the regulation of the skeleton in female mice. J Endocrinol: 2001; 171 2 229 236 (Pubitemid 33061699)
50. Bryzgalova G, Lundholm L, Portwood N., et al. Mechanisms of antidiabetogenic and body weight-lowering effects of estrogen in high-fat diet-fed mice. Am J Physiol Endocrinol Metab: 2008; 295 4 E904 E912
51. Lundholm L, Bryzgalova G, Gao H., et al. The estrogen receptor alpha-selective agonist propyl pyrazole triol improves glucose tolerance in ob/ob mice; potential molecular mechanisms. J Endocrinol: 2008; 199 2 275 286
52. Gao H, Bryzgalova G, Hedman E., et al. Long-term administration of estradiol decreases expression of hepatic lipogenic genes and improves insulin sensitivity in ob/ob mice: a possible mechanism is through direct regulation of signal transducer and activator of transcription 3. Mol Endocrinol: 2006; 20 6 1287 1299 (Pubitemid 43801232)
53. Roesch DM. Effects of selective estrogen receptor agonists on food intake and body weight gain in rats. Physiol Behav: 2006; 87 1 39 44 (Pubitemid 41797720)
54. Harris HA, Katzenellenbogen JA, Katzenellenbogen BS. Characterization of the biological roles of the estrogen receptors, ERalpha and ERbeta, in estrogen target tissues in vivo through the use of an ERalpha-selective ligand. Endocrinology: 2002; 143 11 4172 4177 (Pubitemid 35239546)
55. Kushner PJ, Agard DA, Greene GL., et al. Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol: 2000; 74 5 311 317 (Pubitemid 32126243)
56. McKay LI, Cidlowski JA. Cross-talk between nuclear factor-kappa B and the steroid hormone receptors: mechanisms of mutual antagonism. Mol Endocrinol: 1998; 12 1 45 56 (Pubitemid 28124778)
57. Cvoro A, Tzagarakis-Foster C, Tatomer D, Paruthiyil S, Fox MS, Leitman DC. Distinct roles of unliganded and liganded estrogen receptors in transcriptional repression. Mol Cell: 2006; 21 4 555 564 (Pubitemid 43228010)
58. Krishnan V, Wang X, Safe S. Estrogen receptor-Sp1 complexes mediate estrogen-induced cathepsin D gene expression in MCF-7 human breast cancer cells. J Biol Chem: 1994; 269 22 15912 15917 (Pubitemid 24202193)
59. Carroll JS, Liu XS, Brodsky AS., et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell: 2005; 122 1 33 43 (Pubitemid 40977938)
60. Laganire J, Deblois G, Lefebvre C, Bataille AR, Robert F, Gigure V. From the cover: Location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response. Proc Natl Acad Sci U S A: 2005; 102 33 11651 11656 (Pubitemid 41170781)
61. Lonard DM, Lanz RB, OMalley BW. Nuclear receptor coregulators and human disease. Endocr Rev: 2007; 28 5 575 587 (Pubitemid 47236337)
62. Kang YK, Guermah M, Yuan CX, Roeder RG. The TRAP/Mediator coactivator complex interacts directly with estrogen receptors alpha and beta through the TRAP220 subunit and directly enhances estrogen receptor function in vitro. Proc Natl Acad Sci U S A: 2002; 99 5 2642 2647 (Pubitemid 34240514)
63. Levine M, Tjian R. Transcription regulation and animal diversity. Nature: 2003; 424 6945 147 151 (Pubitemid 36858677)
64. Shibata H, Spencer TE, Oate SA., et al. Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. Recent Prog Horm Res: 1997; 52 141 164; discussion 164165 (Pubitemid 127470209)
65. Billon N, Dani C. Developmental origins of the adipocyte lineage: new insights from genetics and genomics studies. Stem Cell Rev: 2011;; March 2 (Epub ahead of print)
66. Vivar OI, Zhao X, Saunier EF., et al. Estrogen receptor beta binds to and regulates three distinct classes of target genes. J Biol Chem: 2010; 285 29 22059 22066
67. Charn TH, Liu ET, Chang EC, Lee YK, Katzenellenbogen JA, Katzenellenbogen BS. Genome-wide dynamics of chromatin binding of estrogen receptors alpha and beta: mutual restriction and competitive site selection. Mol Endocrinol: 2010; 24 1 47 59
68. Liu Y, Gao H, Marstrand TT., et al. The genome landscape of ERalpha- and ERbeta-binding DNA regions. Proc Natl Acad Sci U S A: 2008; 105 7 2604 2609 (Pubitemid 351520560)
69. Paruthiyil S, Cvoro A, Zhao X., et al. Drug and cell type-specific regulation of genes with different classes of estrogen receptor beta-selective agonists. PLoS ONE: 2009; 4 7 e6271
70. Monroe DG, Secreto FJ, Subramaniam M, Getz BJ, Khosla S, Spelsberg TC. Estrogen receptor alpha and beta heterodimers exert unique effects on estrogen- and tamoxifen-dependent gene expression in human U2OS osteosarcoma cells. Mol Endocrinol: 2005; 19 6 1555 1568 (Pubitemid 41002985)
71. Krum SA, Miranda-Carboni GA, Lupien M, Eeckhoute J, Carroll JS, Brown M. Unique ERalpha cistromes control cell type-specific gene regulation. Mol Endocrinol: 2008; 22 11 2393 2406
72. Lupien M, Brown M. Cistromics of hormone-dependent cancer. Endocr Relat Cancer: 2009; 16 2 381 389
73. Carroll JS, Meyer CA, Song J., et al. Genome-wide analysis of estrogen receptor binding sites. Nat Genet: 2006; 38 11 1289 1297 (Pubitemid 44646291)
74. Lupien M, Eeckhoute J, Meyer CA., et al. FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell: 2008; 132 6 958 970 (Pubitemid 351391952)
75. Welboren WJ, van Driel MA, Janssen-Megens EM., et al. ChIP-Seq of ERalpha and RNA polymerase II defines genes differentially responding to ligands. EMBO J: 2009; 28 10 1418 1428
76. Lin CY, Vega VB, Thomsen JS., et al. Whole-genome cartography of estrogen receptor alpha binding sites. PLoS Genet: 2007; 3 6 e87
77. Levy N, Zhao X, Tang H, Jaffe RB, Speed TP, Leitman DC. Multiple transcription factor elements collaborate with estrogen receptor alpha to activate an inducible estrogen response element in the NKG2E gene. Endocrinology: 2007; 148 7 3449 3458
78. Smith CL, OMalley BW. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev: 2004; 25 1 45 71 (Pubitemid 38292038)
79. Bulynko YA, OMalley BW. Nuclear receptor coactivators: structural and functional biochemistry. Biochemistry: 2010;; December 29 (Epub ahead of print)
80. Misiti S, Schomburg L, Yen PM, Chin WW. Expression and hormonal regulation of coactivator and corepressor genes. Endocrinology: 1998; 139 5 2493 2500 (Pubitemid 28513777)
81. Molenda HA, Kilts CP, Allen RL, Tetel MJ. Nuclear receptor coactivator function in reproductive physiology and behavior. Biol Reprod: 2003; 69 5 1449 1457 (Pubitemid 37362825)
82. Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. Science: 2002; 295 5564 2465 2468 (Pubitemid 34270263)
83. Karmakar S, Foster EA, Smith CL. Unique roles of p160 coactivators for regulation of breast cancer cell proliferation and estrogen receptor-alpha transcriptional activity. Endocrinology: 2009; 150 4 1588 1596
84. Al-Dhaheri M, Wu J, Skliris GP., et al. CARM1 is an important determinant of ER-dependent breast cancer cell differentiation and proliferation in breast cancer cells. Cancer Res: 2011; 71 6 2118 2128
85. Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol: 2010; 28 10 1057 1068